Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS) - Benjamin Rolles; Jan Philipp Bewersdorf; Tariq Kewan; Ondrej Blaha; Jessica M. Stempel; Luca Lanino; Najla H. Al Ali; Amy E. DeZern; Mikkael A. Sekeres; Geoffrey L. Uy; Samuel Urrutia; Hetty E. Carraway; et al. (American Journal of Hematology, 2026)